Daniel Barry, PhD

Co-founder & Chief Scientist

Daniel Barry is Bioinformax’s co-founder and Chief Scientist, where he leads the development of tools and methodologies to translate traditional scientific workflows into Next Generation Workflows comprising the latest in multi-cloud and serverless technologies.

He completed his Doctor of Philosophy from the IMB at The University of Queensland, in protein biochemistry, then spent more than ten years at Queensland universities researching the genomics of bacteria and plants. This included studying the transcriptome of transgenic sugarcane using next generation sequencing technologies.

In his role at Bioinformax he continues to drive the advancement of computational technology to assist in the growth and development in genomics and all sciences that make regular use of programmatic workflows.

Selected Publications:

Solution Structure of the Cyclotide Palicourein Solution structure of the cyclotide palicourein: implications for the development of a pharmaceutical framework Linearization of a Naturally Occurring Circular Protein Maintains Structure but Eliminates Hemolytic Activity Structure‐Function Studies of the Plant Cyclotides: The Role of a Circular Protein Backbone Discovery and structures of the cyclotides: Novel macrocyclic peptides from plants

Brad Vose

Co-founder & Chief Technology Officer

Brad Vose is Bioinformax's co-founder and Chief Technology Officer, where he leads the development of our technology infrastructure and Next Generation Workflows. Brad is a full stack software developer, with experience in the development and deployment of specialised serverless functions for scientists.

He has university degrees in IT and International Business and has immeasureable interest in automation and user experience.

No image found

Michael Korsinczky, PhD

Co-founder & Business Development

Michael Korsinczky is Bioinformax's co-founder and strategic business advisor. He draws on his years of experience in business and investing in creating a construction and design business.

Michael completed a Doctor of Philosophy from the IMB at The University of QUeensland in biochemistry and has experience as a bioinformatician in the Australian Army.

Selected Publications:

Comparative genomics of the neglected human malaria parasite Plasmodium vivax A Novel Plasmodium falciparum Expression System for Assessing Antifolate Resistance Caused by Mutant P. vivax Dihydrofolate Reductase–Thymidylate Synthase Discovery of an MIT-like atracotoxin family: Spider venom peptides that share sequence homology but not pharmacological properties with AVIT family proteins Disulfide Bond Mutagenesis and the Structure and Function of the Head-to-Tail Macrocyclic Trypsin Inhibitor SFTI-1 Sunflower trypsin inhibitor-1 Sulfadoxine Resistance in Plasmodium vivax Is Associated with a Specific Amino Acid in Dihydropteroate Synthase at the Putative Sulfadoxine-Binding Site Enzymatic Cyclization of a Potent Bowman-Birk Protease Inhibitor, Sunflower Trypsin Inhibitor-1, and Solution Structure of an Acyclic Precursor Peptide Mutations in Cytochrome b Resulting in Atovaquone Resistance Are Associated with Loss of Fitness in Plasmodium falciparum Solution structures by 1H NMR of the novel cyclic trypsin inhibitor SFTI-1 from sunflower seeds and an acyclic permutant Mutations in Plasmodium falciparum Cytochrome b That Are Associated with Atovaquone Resistance Are Located at a Putative Drug-Binding Site A single amino acid change in a chymotrypsin prevents plant proteinase inhibitor binding Enzymatic Cyclisation of the Potent Bowman-Birk Protease Inhibitor SFTI-1 and Solution Structure of an Acyclic Precursor Peptide Enzymatic Cyclisation of the Potent Bowman-Birk Protease Inhibitor SFTI-1 and Solution Structure of an Acyclic Precursor Peptide